Introduction to LOC100128317 (G100128317)
Introduction to LOC100128317
LOC100128317, also known as lncRNA-XIST, is a long non-coding RNA that has gained significant attention in the field of biomedical research. This article aims to explore the role of LOC100128317 as a potential drug target or biomarker in various diseases and conditions.
What is LOC100128317?
LOC100128317 is a gene that encodes the long non-coding RNA X-inactive specific transcript (XIST). It is located on the X chromosome and plays a crucial role in X chromosome inactivation during embryonic development in females. XIST is responsible for silencing one of the two X chromosomes in cells of female mammals to achieve dosage compensation between males and females.
Role in Disease:
Apart from its role in X chromosome inactivation, LOC100128317 has been implicated in various disease processes. Numerous studies have shown dysregulation of LOC100128317 in cancer, neurodegenerative disorders, cardiovascular diseases, and immune-related conditions.
In cancer, LOC100128317 has been found to act as a tumor suppressor or oncogene, depending on the specific context and cancer type. For example, in breast cancer, LOC100128317 has been shown to inhibit tumor growth and metastasis through its role in chromatin remodeling and epigenetic regulation. On the other hand, in colorectal cancer, LOC100128317 has been found to promote cancer progression and invasion. These contrasting roles of LOC100128317 in different cancer types suggest its potential as a therapeutic target or prognostic biomarker.
In neurodegenerative disorders like Alzheimer's and Parkinson's disease, LOC100128317 has been identified as a potential biomarker for disease progression and diagnosis. Studies have shown altered levels of LOC100128317 in the cerebrospinal fluid and brain tissue of patients with neurodegenerative disorders. This suggests its involvement in the pathological mechanisms underlying these diseases. Further research is ongoing to understand the exact role of LOC100128317 in neurodegenerative disorders and whether it can serve as a target for novel therapeutic interventions.
Cardiovascular diseases, including heart failure and atherosclerosis, are leading causes of morbidity and mortality worldwide. Research has shown a potential involvement of LOC100128317 in the development and progression of these conditions. In heart failure, LOC100128317 has been found to regulate cardiac hypertrophy and fibrosis. Additionally, altered expression levels of LOC100128317 have been observed in the blood and myocardium of patients with heart failure, suggesting its potential as a diagnostic biomarker. Similarly, in atherosclerosis, LOC100128317 has been associated with plaque stability and the inflammatory response in vascular endothelial cells. This highlights its potential as a therapeutic target for preventing and treating cardiovascular diseases.
The immune system plays a crucial role in maintaining overall health and defending against infection and disease. Dysregulation of immune responses can lead to various immune-related conditions, such as autoimmune diseases and inflammatory disorders. Recent studies have shown the involvement of LOC100128317 in immune regulation. In autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, altered expression levels of LOC100128317 have been observed in immune cells, suggesting its potential as a biomarker for disease activity and response to treatment. Furthermore, recent research has also implicated LOC100128317 in modulating the inflammatory response in immune cells, making it an attractive target for therapeutic intervention in various immune-related conditions.
LOC100128317, also known as lncRNA-XIST, is a long non-coding RNA that plays diverse roles in various diseases and conditions. Its dysregulation has been observed in cancer, neurodegenerative disorders, cardiovascular diseases, and immune-related conditions. Understanding the exact mechanisms underlying the involvement of LOC100128317 in disease pathogenesis can provide new avenues for therapeutic interventions and the development of diagnostic and prognostic biomarkers. Further research is needed to uncover the precise role of LOC100128317 and explore its potential in personalized medicine.
Protein Name: Uncharacterized LOC100128317
More Common Targets
LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249 | LOC100132287 | LOC100132356 | LOC100132609 | LOC100132626 | LOC100132651 | LOC100132686 | LOC100132741 | LOC100132781 | LOC100132797 | LOC100133077 | LOC100133165 | LOC100133177 | LOC100133284 | LOC100133331 | LOC100133920 | LOC100134317 | LOC100134368 | LOC100134391 | LOC100134868 | LOC100190986 | LOC100233156 | LOC100240728 | LOC100240734 | LOC100240735 | LOC100271840 | LOC100272216 | LOC100272217 | LOC100286922 | LOC100287036 | LOC100287290 | LOC100287329 | LOC100287413 | LOC100287792 | LOC100287834 | LOC100287846 | LOC100287944 | LOC100288069 | LOC100288162 | LOC100288208 | LOC100288637 | LOC100288656 | LOC100289230 | LOC100289283 | LOC100289308 | LOC100289333